Home › NCT07218471
Cannabis Reduction and Functional Outcomes
Prospective Changes in Patient-reported and Objective Functioning Following Reduction of Cannabis Use
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18+ * Urinary cannabinoid level ≥ 50 ng/mL * DSM-5 diagnosis of CUD (mild, moderate, or severe) * Willingness to attempt cannabis reduction * Completion of Intake Visit Exclusion Criteria: * Serious medical/psychiatric conditions * Pregnancy or breastfeeding * Use of cannabis in past 30 days was for medical purposes only * Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition * Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz
About the study
This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.
What is being tested
- CBT4CBT (Computerized Cognitive Behavioral Therapy) (behavioral)
- Motivational Interviewing (behavioral)
- Contingency Management (behavioral)
Sponsor: Medical University of South Carolina · Participants: 176 · Started: Mar 13, 2026
Contact the study team
- Rachel Tomko, PhD · Phone: (843) 792-5447
- Erin McClure, PhD · Phone: (843) 792-7192
Official record on ClinicalTrials.gov — NCT07218471
Locations in the U.S.
| South Carolina | Medical University of South Carolina, Charleston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.